Fast Facts
  • In collaboration with MedImmune, Crucell is developing antibodies for the treatment and prevention of hospital-acquired bacterial infection.
  • The antibodies were discovered using Crucell’s MAbstract® technology.
  • The antibodies are currently in a pre-clinical stage of development.
Description

In 2005, Crucell announced the initiation of several new antibody discovery programs in the field of hospital-acquired infections.

 

In October 2007, MedImmune and Crucell entered into an exclusive license and research collaboration to further develop and commercialize one of Crucell’s panels of bacterial antibodies primarily for the treatment and prevention of hospital-acquired bacterial infection.
Development Rationale
The rise in hospital-acquired infections caused by antibiotic-resistant bacteria presents an opportunity for the development of alternative treatments replacing or complementing antibiotics.
Development Status
The anti-bacterial antibodies are currently in a pre-clinical stage of development, with pre-clinical model validation ongoing.
About Hospital-Acquired Bacterial Infections
In the U.S. and Europe, hospital-acquired bacterial infections affect about two million patients per year, causing more than 200,000 deaths. Attributable costs amount to more than US$ 5 billion per year in the U.S. alone. Antibiotic-resistant bacteria increase the severity of disease, escalating mortality rates and driving up costs.